Please select the option that best describes you:
At what point during first-line treatment with mono-immunotherapy for oligometastatic NSCLC is the ideal time to consider consolidative radiation/SBRT to the primary and oligometastatic sites?
Much of this approach was designed with cytotoxic chemotherapy in mind -- wait "x" cycles, assess response, deliver radiation after chemotherapy. How do you view this concept for immunotherapy cycles? Would you stop immunotherapy during consolidative treatment?
Answer from: Radiation Oncologist at Academic Institution
What I do in general first and foremost is judge whether or not it’s appropriate to offer consolidation: reasonable indications thus far have been: oligometastatic disease status at presentation, oligoprogressive disease after therapy, limited # of sites to irradiate, safe to deliver SBRT in t...
Sign in or Register to read more
Answer from: Radiation Oncologist at Academic Institution
Agree with Dr Lee above. I see no reason why one cannot extrapolate from the Gomez data, which gave 3 months of targeted therapy (or 4 cycles platinum doublet chemo), assessed response, and treated non-progressors to the primary and oligomets